Journal of | | Open Access Pub

Full Text Article Abstract Introduction Materials and Methods Results Discussion Reference

Nanotechnology Meets Immunotherapy: CAR-T Cells Technology And Beyond

Rizzello Loris ¹

1 Department of Chemistry, University College London (UCL), 20 Gordon Street, WC1H 0AJ - London (UK)

Abstract

The crusade against cancer has a new army: immunotherapy. The rational design is very simple, but brilliant at the same time. Extract the patients T-cells, reprogram them in vitro for the expression of highly specific receptors against cancer, perfuse them back to the patient. As a result, T-cells are now instructed to selectively kill circulating tumor cells, while avoiding potential side effects. This Fairy Tale however does not lack of drawbacks and limitations. First, malignant progression can be accompanied by profound immune suppression, which counteracts the immune system-mediated tumor elimination. Second, the immune cells modification does not match high standards in terms of safety for humans. Here, nanotech can fill these gaps, and help immunotherapy to be safer and more effective.

Author Contributions

Received Jan 28, 2018 Accepted Feb 24, 2018 Published Mar 05, 2018

Copyright© 2018 Rizzello Loris.
License
This work is licensed under a Creative Commons Attribution 4.0 International License. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing interests

The authors have declared that no competing interests exist.

Funding Interests:

Citation:

Rizzello Loris (2018) Nanotechnology Meets Immunotherapy: CAR-T Cells Technology And Beyond Journal of Biomaterials . - 1(1):1-6

DOI

Journal of Biomaterials